Expert Rev Clin Immunol:过敏性鼻炎患者中B7同源体1与白介素-4、白介素-17和干扰素γ关系研究

2019-07-15 AlexYang MedSci原创

过敏性鼻炎是最常见的特应性疾病和最常见的慢性过敏性疾病。该疾病的病因学包括细胞因子水平的增加,包括IL-4、IL-13和IL-17;以及B7同源体1(B7-H1)或者程序性细胞死亡-1配体(PD-L1)的减少。最近,有研究人员确定了细胞因子与PD-L1之间的关系。研究人员筛选了80名符合标准的过敏性鼻炎患者。平均年龄为28.5±1.3岁。在这80名受试者中,46(57.5%)名为男性。研究发现,在

过敏性鼻炎是最常见的特应性疾病和最常见的慢性过敏性疾病。该疾病的病因学包括细胞因子水平的增加,包括IL-4、IL-13和IL-17;以及B7同源体1(B7-H1)或者程序性细胞死亡-1配体(PD-L1)的减少。最近,有研究人员确定了细胞因子与PD-L1之间的关系。

研究人员筛选了80名符合标准的过敏性鼻炎患者。平均年龄为28.5±1.3岁。在这80名受试者中,46(57.5%)名为男性。研究发现,在过敏性鼻炎患者中,SPD-L1和INFγ、IL-4和IL-17具有明显的关系(P<0.05)。基于疾病严重度的统计学分析表明,SPD-L1和INFγ在3个疾病严重度水平上具有正相关关系(P<0.001)。考虑到疾病持续的时间,SPD-L1与INFγ在永久性和间歇性组中也存在显著的正相关关系。

最后,研究人员指出,由于PD-L1分子与IL-4和IL-17炎症细胞因子之间具有负相关关系,PD-L1也许在过敏性鼻炎中具有保护性作用,尽管其详细的机制还需进一步的详细研究。

原始出处:

Nasiri Kalmarzi R, Fakhimi R, Manouchehri F et al. The relationship between B7 homologous 1 with interleukin-4, interleukin-17 and interferon gamma in patients with allergic rhinitis. Expert Rev Clin Immunol. 04 Jul 2019

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1728048, encodeId=68b41e28048d6, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Oct 09 18:50:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047136, encodeId=da5e204e13633, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Jan 21 12:50:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651337, encodeId=c87c165133ece, content=<a href='/topic/show?id=6eefe162275' target=_blank style='color:#2F92EE;'>#白介素-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71622, encryptionId=6eefe162275, topicName=白介素-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=859f24174096, createdName=zhangph, createdTime=Thu Jul 18 03:50:00 CST 2019, time=2019-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372126, encodeId=4c5a13e212689, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Wed Jul 17 03:50:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369769, encodeId=e67f369e6922, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ce65106991, createdName=14607dd8m74暂无昵称, createdTime=Tue Jul 16 09:37:15 CST 2019, time=2019-07-16, status=1, ipAttribution=)]
    2019-10-09 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1728048, encodeId=68b41e28048d6, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Oct 09 18:50:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047136, encodeId=da5e204e13633, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Jan 21 12:50:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651337, encodeId=c87c165133ece, content=<a href='/topic/show?id=6eefe162275' target=_blank style='color:#2F92EE;'>#白介素-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71622, encryptionId=6eefe162275, topicName=白介素-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=859f24174096, createdName=zhangph, createdTime=Thu Jul 18 03:50:00 CST 2019, time=2019-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372126, encodeId=4c5a13e212689, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Wed Jul 17 03:50:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369769, encodeId=e67f369e6922, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ce65106991, createdName=14607dd8m74暂无昵称, createdTime=Tue Jul 16 09:37:15 CST 2019, time=2019-07-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1728048, encodeId=68b41e28048d6, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Oct 09 18:50:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047136, encodeId=da5e204e13633, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Jan 21 12:50:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651337, encodeId=c87c165133ece, content=<a href='/topic/show?id=6eefe162275' target=_blank style='color:#2F92EE;'>#白介素-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71622, encryptionId=6eefe162275, topicName=白介素-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=859f24174096, createdName=zhangph, createdTime=Thu Jul 18 03:50:00 CST 2019, time=2019-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372126, encodeId=4c5a13e212689, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Wed Jul 17 03:50:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369769, encodeId=e67f369e6922, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ce65106991, createdName=14607dd8m74暂无昵称, createdTime=Tue Jul 16 09:37:15 CST 2019, time=2019-07-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1728048, encodeId=68b41e28048d6, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Oct 09 18:50:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047136, encodeId=da5e204e13633, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Jan 21 12:50:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651337, encodeId=c87c165133ece, content=<a href='/topic/show?id=6eefe162275' target=_blank style='color:#2F92EE;'>#白介素-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71622, encryptionId=6eefe162275, topicName=白介素-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=859f24174096, createdName=zhangph, createdTime=Thu Jul 18 03:50:00 CST 2019, time=2019-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372126, encodeId=4c5a13e212689, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Wed Jul 17 03:50:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369769, encodeId=e67f369e6922, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ce65106991, createdName=14607dd8m74暂无昵称, createdTime=Tue Jul 16 09:37:15 CST 2019, time=2019-07-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1728048, encodeId=68b41e28048d6, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Oct 09 18:50:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047136, encodeId=da5e204e13633, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Jan 21 12:50:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651337, encodeId=c87c165133ece, content=<a href='/topic/show?id=6eefe162275' target=_blank style='color:#2F92EE;'>#白介素-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71622, encryptionId=6eefe162275, topicName=白介素-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=859f24174096, createdName=zhangph, createdTime=Thu Jul 18 03:50:00 CST 2019, time=2019-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372126, encodeId=4c5a13e212689, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Wed Jul 17 03:50:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369769, encodeId=e67f369e6922, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ce65106991, createdName=14607dd8m74暂无昵称, createdTime=Tue Jul 16 09:37:15 CST 2019, time=2019-07-16, status=1, ipAttribution=)]
    2019-07-16 14607dd8m74暂无昵称

    学习了,谢谢分享

    0

相关资讯

Allergy Asthma Clin Immunol:屋尘螨过敏性鼻炎的舌下免疫治疗药片研究

最近,有研究人员进行了成本最小化分析来评估利用SQ 屋尘螨舌下免疫治疗(SQ HDM SLIT)来对HDM诱导的过敏性鼻炎进行治疗的经济影响,而在研究所在地区,屋尘螨舌下免疫治疗(HDM SCIT)已经是一个可以选择的疗法。CMA被认为是合适的并且是基于SQ HDM SLIT药片治疗与HDM SCIT具有相当的疗效。研究人员在评估模型中采用了社会视角,包括了药物的相关花费、健康医疗服务和产出损失。

Int Arch Allergy Immunol:Zeste同源体2增强子的表观修饰能够调节树突细胞的激活

过敏原免疫疗法(AIT)是目前过敏性鼻炎(AR)唯一的病因学和可能的治愈疗法。最近,有研究人员探索调查了AIT中,表观调节因子zeste同源体2增强子(EZH2)在树突细胞(DCs)激活中的作用。研究包括了56名AR患者的临床信息,他们均接受了AIT治疗。其中,30名受试者进行的是皮下免疫治疗(SCTI),26名受试者进行的是舌下免疫治疗(SLIT)。研究发现,EZH2的表达在循环mDCs和pDC

Allergy:成年人哮喘风险与过敏性多重并发症和年龄的关系分析

最近,有研究人员研究了过敏性多重并发症与成年人起始的哮喘的相关性,并考虑了过敏性疾病的数量和年龄的影响。研究是一个基于群体的研究,包括了1205名年龄大于30岁的成年人,他们均诊断为哮喘(年龄范围30-93)。另外,与性别、年龄和居住地匹配的对照包括了2050名。研究人员根据调查问卷确定了过敏性鼻炎(AR)、过敏性结膜炎(AC)和过敏性皮炎(AD)的情况。研究最后包括了1118个哮喘案例和阈值匹配

Int Arch Allergy Immunol:过敏性鼻炎对鼻腔黏液纤毛清除时间的影响研究

鼻腔黏液纤毛清除是气道中的最重要的保护功能之一。之前的研究探索了过敏性鼻炎(AR)对鼻腔黏液纤毛清除时间(MCT)的影响,但是患者群体小且结果存在矛盾。最近,他们确定了是否AR对MCT具有影响。研究包括了842名AR儿童,总共有96名没有过敏性鼻炎历史的儿童作为对照组。研究发现,与对照相比(平均值±SD:7.25±4.3 ),鼻MCT在AR患者中显著更长(平均值±SD:10.5±5.65分钟)。嗜

Exp Physiol:卵清蛋白诱导的过敏性鼻炎中的MiR-199-3p/Dnmt3a/STAT3信号通路研究

之前的研究阐释了表观遗传修饰在过敏性鼻炎(AR)中的作用,尤其是DNA甲基化。然而,详细的机制仍旧不清楚。最近,有研究人员利用卵清蛋白诱导的AR小鼠探索了上述详细机制,并且利用行为评分、组胺和其他炎症因子来确定建模是否成功。另外,还利用实时定量、蛋白免疫印迹和亚硫酸氢盐测序PCR(BSP)的双报告子试验检测了相关基因和蛋白的表达、甲基化情况和靶标情况。研究发现,行为评分和分子标记均表明建模成功。D

盘点:过敏性鼻炎进展

过敏性鼻炎主要由IgE介导的介质(主要是组胺)释放,并有多种免疫活性细胞和细胞因子等参与的鼻黏膜非感染性炎性疾病。其发生的必要条件有特异性抗原即引起机体免疫反应的物质、特应性个体、特异性抗原与特应型个体二者相遇。过敏性鼻炎是一个全球性健康问题,可导致许多疾病和劳动力丧失。梅斯医学小编整理了近期过敏性鼻炎的研究进展,与大家一起分享学习!【1】Clin Mol Allergy:呼吸道过敏性疾病患者